RxDoctor Payments Data

Sowmya Thanneeru, MD

Internal Medicine · Scranton, PANPI 1962842898

Payments from drug & device makers

$285in general payments, 2019–2025

Across 17 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$66
  • Amgen$44
  • Shire North American Group Inc$30
  • Daiichi Sankyo Inc.$23
  • AbbVie$23
  • Pfizer$18
  • plus $81 from 5 others

What the payments were for

  • Food & beverage$285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$285 in reported general payments places this provider in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$98,040
Medicare patients
345
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$72,834
TrulicityDulaglutide40$72,372
EliquisApixaban46$52,796
MounjaroTirzepatide21$35,473
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$24,125
FarxigaDapagliflozin Propanediol12$20,292
XareltoRivaroxaban13$19,255
JardianceEmpagliflozin16$15,616
Breo ElliptaFluticasone/Vilanterol13$9,682
MyrbetriqMirabegron15$8,396
JanumetSitagliptin Phos/Metformin Hcl12$7,204
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$5,896
Budesonide11$4,703
Omeprazole254$4,121
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$3,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$66$107,84561 claims
Novo NordiskOzempic$16$72,83444 claims
PfizerEliquis, Paxlovid$18$55,70659 claims
Astellas Pharma US IncMyrbetriq$17$8,39615 claims
MerckJanumet$16$7,20412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →